CN118401518A - 一种glp-1受体激动剂的结晶形式及其制备方法 - Google Patents

一种glp-1受体激动剂的结晶形式及其制备方法 Download PDF

Info

Publication number
CN118401518A
CN118401518A CN202280084770.1A CN202280084770A CN118401518A CN 118401518 A CN118401518 A CN 118401518A CN 202280084770 A CN202280084770 A CN 202280084770A CN 118401518 A CN118401518 A CN 118401518A
Authority
CN
China
Prior art keywords
compound
methyl
ray powder
powder diffraction
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280084770.1A
Other languages
English (en)
Chinese (zh)
Inventor
徐谷军
陆伟栋
杨俊然
杜振兴
邵启云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN118401518A publication Critical patent/CN118401518A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280084770.1A 2021-12-23 2022-12-23 一种glp-1受体激动剂的结晶形式及其制备方法 Pending CN118401518A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111586541 2021-12-23
CN2021115865413 2021-12-23
PCT/CN2022/141407 WO2023116879A1 (zh) 2021-12-23 2022-12-23 一种glp-1受体激动剂的结晶形式及其制备方法

Publications (1)

Publication Number Publication Date
CN118401518A true CN118401518A (zh) 2024-07-26

Family

ID=86901327

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280084770.1A Pending CN118401518A (zh) 2021-12-23 2022-12-23 一种glp-1受体激动剂的结晶形式及其制备方法

Country Status (10)

Country Link
US (1) US20250049778A1 (enExample)
EP (2) EP4455140B1 (enExample)
JP (1) JP2024547112A (enExample)
KR (1) KR20240125004A (enExample)
CN (1) CN118401518A (enExample)
AU (1) AU2022422997A1 (enExample)
CA (1) CA3241677A1 (enExample)
MX (1) MX2024007907A (enExample)
TW (1) TW202328115A (enExample)
WO (1) WO2023116879A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024340407A1 (en) 2023-09-14 2026-04-23 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
JP2023528565A (ja) * 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
PL4157832T3 (pl) * 2020-05-27 2024-12-16 Qilu Regor Therapeutics Inc. Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowania
CN119930605A (zh) * 2020-09-01 2025-05-06 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2022228490A1 (zh) * 2021-04-30 2022-11-03 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
KR20240125004A (ko) 2024-08-19
EP4455140B1 (en) 2026-04-01
US20250049778A1 (en) 2025-02-13
EP4455140A1 (en) 2024-10-30
EP4725484A2 (en) 2026-04-15
EP4455140A4 (en) 2025-04-09
CA3241677A1 (en) 2023-06-29
JP2024547112A (ja) 2024-12-26
TW202328115A (zh) 2023-07-16
WO2023116879A1 (zh) 2023-06-29
AU2022422997A1 (en) 2024-07-11
MX2024007907A (es) 2024-07-12

Similar Documents

Publication Publication Date Title
EP4455141B1 (en) Pharmaceutically acceptable salt and crystalline form of a glp-1 receptor agonist for the treatment of diabetes
EP4455140A1 (en) Crystalline form of glp-1 receptor agonist and preparation method therefor
EP4332102A1 (en) Isoquinolone compound and use thereof
CN119654319A (zh) 一种cdk抑制剂及其磷酸盐的多晶型
EP2635580B1 (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
EP3022209B1 (en) Dolutegravir potassium salt
TWI826013B (zh) 咪唑啉酮衍生物的晶型
CA3225268A1 (en) Salt types of tricyclic tetrahydro isoquinoline derivative
EP4538277A1 (en) Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt
TWI914461B (zh) 一種吲唑類衍生物的藥學上可接受鹽、結晶形式及其製備方法
EP4682147A1 (en) Pharmaceutically acceptable salt and crystal form of 1,4-dihydro-1,6-naphthyridine amide compound and preparation method therefor
EP3604284B1 (en) Crystalline eltrombopag monoethanolamine salt form d
EP4610257A1 (en) Crystal form of isoquinolinone compound and preparation method therefor
CN114644616B (zh) 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法
CN113527265B (zh) 一种氘代吡咯烷酮衍生物、药物组合物及其用途
CN118556054A (zh) 一种p2x3受体拮抗剂的结晶形式及其制备方法
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
WO2024159211A1 (en) Methods and compositions for treatment of obesity and diseases associated with fat cell enlargement
CN120535504A (zh) 一种p38α-MK2抑制剂的晶型及其制备方法和应用
EP4644374A1 (en) Naphthylamide compound, and preparation method therefor and use thereof
KR20250112264A (ko) 퀴놀린아민계 화합물의 결정형 및 이의 제조 방법
CN119798232A (zh) N-甲酰胺基吡唑啉化合物的晶型及其制备方法和应用
EP4711372A1 (en) Crystal form of heterocyclic compound, salt thereof, crystal form of salt thereof, and use
JP2013184934A (ja) オキサジアゾリジンジオン化合物の新規な塩及びその結晶
CN113248488A (zh) 新型杂环酰胺哌啶类衍生物及其制备方法和在降血糖药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40114744

Country of ref document: HK